Exact Sciences (NASDAQ:EXAS) Issues Earnings Results, Beats Expectations By $0.23 EPS

Exact Sciences (NASDAQ:EXAS) issued its quarterly earnings results on Wednesday. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23, Zacks reports. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences updated its FY 2025 guidance to EPS.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $46.04 on Thursday. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of -40.81 and a beta of 1.24. The company has a 50-day simple moving average of $55.41 and a two-hundred day simple moving average of $60.10. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62.

Wall Street Analyst Weigh In

EXAS has been the subject of several analyst reports. The Goldman Sachs Group lowered their target price on Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Jefferies Financial Group lifted their price objective on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Barclays lowered their price objective on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a research report on Thursday. Evercore ISI lowered their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Piper Sandler reduced their target price on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $72.06.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.